SEC Form 4 · accession 0001209191-18-005678
Tvardi Therapeutics, Inc. · TVRD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Derek T Chalmers
Officer — President & CEO · Director
Period of report
Jan 24, 2018
Accepted (ET)
Jan 26, 2018 · 5:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 24, 2018 | S | 12,500 | $15.00 | D | 1,073,792 | D | |
| Common Stock | Jan 25, 2018 | M | 3,000 | $6.00 | A | 1,076,792 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $6.00 | Jan 25, 2018 | M | 3,000 | D | — | Mar 30, 2026 | Common Stock | 3,000 | 191,000 | D |
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017.
- F2The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.